Dr David Yeung        Dr Devendra Hiwase     Dr Agnes Yong

Session 2: TKI resistance / failure

• When frontline therapy fails 
  (Dr David Yeung)
• CML - beyond chronic phase
  (Dr Devendra Hiwase)
• Allograft - still a role in CML?
  (Dr Agnes Yong)

Prof. Tim Hughes

 Session 1: Frontline CML

• Current clinical issues 
  (Prof. Tim Hughes)

Treatment Outcomes on Bosutinib: Data from the Real World
Jane Apperley, Imperial College, London, UK

• Change in CML survival over time: German studies 
• Patient pathways for tyrosine kinase inhibitors
• Introduction of bosutinib into clinical practice
• Real-World use of bosutinib: UK & Netherlands
• Responses to bosutinib in chronic phase
• Reasons for discontinuation of bosutinib
• Disease progression
• Adverse events on bosutinib
• Overall survival
• Summary and conclusions

This presentation is adapted from one given during the industry sponsored symposium at EHA.

Factors affecting clinical decision making in refractory and relapsed CP-CML patients
Delphine Réa, Centre Hospitalo-Universitaire Saint-Louis, Paris, France

• TKI resistance: significance and definition 
• BCR-ABL1 mutations and resistance to imatinib and 2nd generation TKI's
• Failure of 1st and 2nd generation TKI's
• Mortality and causes of death in CP-CML patients during 2nd or subsequent line TKI
• Responses to 3rd line therapy after resistance or intolerance to 2nd generation TKI
• 5-year results from the PACE study: Responses to ponatinib in CP-CML patients
• Therapeutic innovation: allosteric inhibition of BCR-ABL1 by ABL001
• Conclusion and perspective

This presentation is adapted from one given during the industry sponsored symposium at EHA.